SpectraCure reports positive results from the company's clinical phase 1-study
Today July 2nd, 2019, SpectraCure AB ("Spec") reports positive results and good clinical effects regarding safety in the company's clinical phase 1-study of patients with recurrent prostate cancer.SpectraCure has conducted a clinical phase 1-study on treatment of patients with recurrent prostate cancer with the company's photodynamic therapy (PDT) technology.A total of 11 patients with recurrent prostate cancer were treated with SpectraCure's technology in the phase 1-study, with promising and positive results. This means that the study's primary endpoint on safety was achieved. However,